ADMA Biologics, Inc.
Financials
Valuation Metrics
ADMA Biologics, Inc.'s Market Cap is $2.04B. At end of 2025 it was $4.34B. Ranked #2034 of 3,121 in US market (top 65%), #780 of 1,463 on NASDAQ (top 53%), #141 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 53%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.04B | US#2,034/3,121 Sec#141/266 |
| Revenue | $512M | US#2,242/3,121 Sec#74/266 |
| Net Income | $169M | US#1,372/3,121 Sec#45/266 |
| Total Assets | $684M | US#2,642/3,121 Sec#135/266 |
| Net Assets | $408M | US#2,368/3,121 Sec#133/266 |
| Employees | 640 | US#2,167/3,121 Sec#72/266 |
| Value | ||
| P/E | 12.08x | US#504/3,121 Sec#11/266 |
| P/B | 5.00x | US#2,208/3,121 Sec#140/266 |
| P/S | 3.98x | US#2,056/3,121 Sec#60/266 |
| EV/EBITDA | 8.98x | US#628/3,121 Sec#19/266 |
| FCF Yield | 5.71% | US#1,247/3,121 Sec#40/266 |
| Profitability | ||
| ROE | 41.39% | US#162/3,121 Sec#13/266 |
| ROA | 24.69% | US#57/3,121 Sec#11/266 |
| Op. Margin | 42.26% | US#236/3,121 Sec#13/266 |
| Revenue Growth | 8.04% | US#1,475/3,121 Sec#107/266 |
| Earnings Growth | -19.13% | US#1,544/3,121 Sec#39/266 |
| Financial Health | ||
| Debt Ratio | 67.61% | US#744/3,121 Sec#150/266 |
| Total Debt | $204M | US#2,246/3,121 Sec#94/266 |
| FCF | $116M | US#1,673/3,121 Sec#59/266 |
| Cash | $136M | US#2,017/3,121 Sec#144/266 |
| Current Ratio | 6.97x | US#358/3,121 Sec#111/266 |
| Net Debt/EBITDA | 0.29x | US#700/3,121 Sec#38/266 |
| Performance | ||
| 1Y Return | -43.63% | US#2,823/3,121 Sec#238/266 |
| 1M Return | -9.35% | US#1,928/3,121 Sec#152/266 |
| From 52W High | -55.47% | US#2,856/3,121 Sec#228/266 |
| 1Y MDD | -62.71% | US#2,835/3,121 Sec#221/266 |
| Trading | ||
| Volume | 10,169,498 shares | US#815/3,121 Sec#83/266 |
| Trading Value | $92M | US#1,953/3,121 Sec#151/266 |
| Per Share | ||
| EPS | $0.75 | US#1,769/3,121 Sec#54/266 |
| BPS | $1.82 | US#2,589/3,121 Sec#182/266 |
Company Info
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.